Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.2100 (-2.97%) ($6.0300 - $6.5000) on Fri. Aug. 30, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.89% (three month average) | RSI | 36 | Latest Price | $6.2100(-2.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.945% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) UUP(-6%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.945% (StdDev 3.89%) | Hourly BBV | 0 () | Intraday Trend | -3.6% | | | |
|
1 - 5 Day Possible Target | $-4.72(-176.01%) | Resistance Level | $6.58 | 5 Day Moving Average | $6.16(0.81%) | 10 Day Moving Average | $6.32(-1.74%) | 20 Day Moving Average | $6.58(-5.62%) | To recent high | -30.9% | To recent low | 4.9% | Market Cap | $786m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |